Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1987 Jan;46(1):1–6. doi: 10.1136/ard.46.1.1

Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

A E Gharavi, E N Harris, R A Asherson, G R Hughes
PMCID: PMC1002050  PMID: 3813670

Abstract

Quantitative isotype specific enzyme linked immunosorbent assay (ELISA) was used to determine the distribution of immunoglobulin isotypes and phospholipid specificities of anticardiolipin (anti-CL) antibodies in 40 patients with one or more of the following 'antiphospholipid (anti-PL) antibody associated clinical complications'--namely, thrombosis, fetal loss, thrombocytopenia. Twelve of 40 patients had IgG, IgM, and IgA anti-CL antibodies. Ten patients had IgG and IgM, five patients had IgG and IgA, and three patients had IgM and IgA anti-CL antibodies. There was no statistical association between any single isotype or any group of isotypes with thrombosis, fetal loss, or thrombocytopenia. The presence of IgG anti-CL antibodies in 36 of the 40 patients suggests that this isotype may be most important in determining clinical complications, but there were four patients without IgG anti-CL antibodies who also appeared susceptible to thrombosis, fetal loss, and thrombocytopenia. IgG, IgM, and IgA anti-CL antibodies bound the negatively charged phospholipids, phosphatidylserine and phosphatidylinositol, but not the zwitterionic phospholipid, phosphatidylcholine. There was no significant difference between binding to cardiolipin and binding to other negatively charged phospholipids, suggesting that the specificity of these antibodies is for negatively charged phospholipids in general rather than for cardiolipin in particular.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boey M. L., Colaco C. B., Gharavi A. E., Elkon K. B., Loizou S., Hughes G. R. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1021–1023. doi: 10.1136/bmj.287.6398.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Branch D. W., Scott J. R., Kochenour N. K., Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985 Nov 21;313(21):1322–1326. doi: 10.1056/NEJM198511213132104. [DOI] [PubMed] [Google Scholar]
  3. Canoso R. T., Sise H. S. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982 Sep;13(2):121–129. doi: 10.1002/ajh.2830130204. [DOI] [PubMed] [Google Scholar]
  4. Carreras L. O., Vermylen J. G. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation. Thromb Haemost. 1982 Aug 24;48(1):38–40. [PubMed] [Google Scholar]
  5. Elias M., Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant. Arch Intern Med. 1984 Mar;144(3):510–515. [PubMed] [Google Scholar]
  6. Gastineau D. A., Kazmier F. J., Nichols W. L., Bowie E. J. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. 1985 Jul;19(3):265–275. doi: 10.1002/ajh.2830190308. [DOI] [PubMed] [Google Scholar]
  7. Glueck H. I., Kant K. S., Weiss M. A., Pollak V. E., Miller M. A., Coots M. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med. 1985 Aug;145(8):1389–1395. [PubMed] [Google Scholar]
  8. Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983 Nov 26;2(8361):1211–1214. doi: 10.1016/s0140-6736(83)91267-9. [DOI] [PubMed] [Google Scholar]
  9. Harris E. N., Gharavi A. E., Hughes G. R. Anti-phospholipid antibodies. Clin Rheum Dis. 1985 Dec;11(3):591–609. [PubMed] [Google Scholar]
  10. Harris E. N., Gharavi A. E., Loizou S., Derue G., Chan J. K., Patel B. M., Mackworth-Young C. G., Bunn C. C., Hughes G. R. Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol. 1985 Jan;16(1):1–6. [PubMed] [Google Scholar]
  11. Harris E. N., Gharavi A. E., Tincani A., Chan J. K., Englert H., Mantelli P., Allegro F., Ballestrieri G., Hughes G. R. Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol. 1985 Aug;17(4):155–162. [PubMed] [Google Scholar]
  12. Harris E. N., Loizou S., Englert H., Derue G., Chan J. K., Gharavi A. E., Hughes G. R. Anticardiolipin antibodies and lupus anticoagulant. Lancet. 1984 Nov 10;2(8411):1099–1099. doi: 10.1016/s0140-6736(84)91537-x. [DOI] [PubMed] [Google Scholar]
  13. Koike T., Sueishi M., Funaki H., Tomioka H., Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol. 1984 Apr;56(1):193–199. [PMC free article] [PubMed] [Google Scholar]
  14. Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh. 1969 Jun 15;21(3):482–499. [PubMed] [Google Scholar]
  15. Lockshin M. D., Druzin M. L., Goei S., Qamar T., Magid M. S., Jovanovic L., Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985 Jul 18;313(3):152–156. doi: 10.1056/NEJM198507183130304. [DOI] [PubMed] [Google Scholar]
  16. Mueh J. R., Herbst K. D., Rapaport S. I. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980 Feb;92(2 Pt 1):156–159. doi: 10.7326/0003-4819-92-2-156. [DOI] [PubMed] [Google Scholar]
  17. Norberg R., Gårdlund B., Thorstensson R., Lidman K. Further immunological studies of sera containing anti-mitochondrial antibodies, type M 5. Clin Exp Immunol. 1984 Dec;58(3):639–644. [PMC free article] [PubMed] [Google Scholar]
  18. Polli N., O'Brien M., Tavares de Castro J., Matutes E., San Miguel J. F., Catovsky D. Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. I. Ultrastructural morphology and cytochemistry. Br J Haematol. 1985 Feb;59(2):277–296. doi: 10.1111/j.1365-2141.1985.tb02994.x. [DOI] [PubMed] [Google Scholar]
  19. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zarrabi M. H., Zucker S., Miller F., Derman R. M., Romano G. S., Hartnett J. A., Varma A. O. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979 Aug;91(2):194–199. doi: 10.7326/0003-4819-91-2-194. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES